Module 1: Administrative Information & Prescribing Information.

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) TEMPLATE

1. NAME OF THE MEDICINAL PRODUCT

HABIFEN-600 TABLETS

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film coated tablet contains: Ibuprofen BP 600 mg Excipients Q.S. Erythrosine & Titanium Dioxide (In house)

For a full list of excipients, see Section 6.1.

Sr. No.	Ingredients	Specification	Label claim/Tab	Per dosage	Reason for Inclusion
110.			(in mg)	unit (mg)	Inclusion
1	Ibuprofen	BP	600	600	Medicament
2	Starch	BP		196	Diluent / lubricant
3	Talc	BP		5	Lubricant
4	Methyl Paraben	BP		0.15	Preservative
5	Propyl Paraben	BP		0.15	Preservative
6	Dicalcium Phosphate	BP		200	Diluent
7	Magnesium Stearate	BP		8	Lubricant
8	Sodium Starch Glycolate	BP		5	Lubricant
9	Colloidal Silicon Dioxide	BP		2	Lubricant
10	Stearic Acid	BP		0.1	Binder
11	Ultracoat AQ pink	IHS		30	Coating Material

BP = British Pharmacopeia

IH = In House.

Module 1: Administrative Information & Prescribing Information.

3. PHARMACEUTICAL form

Tablet

Description: Pink coloured, capsule shaped, film coated tablet having a break line on one side of each tablet.

4. Clinical particulars

4.1 Therapeutic indications

Ibuprofen is a Nonsteroidal Anti-inflammatory Drug used in painful and inflammatory conditions. Ibuprofen is used in the management of mild to moderate pain and inflammation in conditions such as dysmenorrhea, migrane, postoperative pain, dental pain, musculoskeletal and joint disorders such as ankylosing spondylitis, osteoarthritis and rheumatoid arthritis including juvenile rheumatoid arthritis, peri-articular disorders such as bursitis and tenosynovitis, and soft tissue disorders such as sprains and strains.

4.2 Posology and method of administration

Posology: 1 Tablet 2 to 3 times a day or as directed by the physician.

Method of administration: Oral

4.3 Contraindications

HABIFEN – 600 is contraindicated in patients with known hypersensitivity to Ibuprofen. HABIFEN – 600 should not be given to patients who have experienced asthma, urticarial or allergic type reactions after taking aspirin or other NSAIDs. Severe rarely fatal, anaphylactic like reactions to NSAIDs have been reported in such patients. HABIFEN – 600 are contraindicated for the treatment of peri – operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Module 1: Administrative Information & Prescribing Information.

4.4 Special warnings and precautions for use.

 ${
m HABIFEN}-600$ should be given with care to the elderly, to patients with asthma or bronchospasm, bleeding disorders, cardiovascular disease, a history of peptic ulceration, and in liver or renal failure.

Care is required in those who are also receiving coumarin anticoagulants.

Patients who are sensitive to aspirin or other NSAIDs should generally not be given Ibuprofen.

Ibuprofen should be discontinued in patients who experience blurred or diminished vision or changes in colour vision. Patients with collagen disease may be at increased risk of developing aseptic meningitis.

4.5 Interaction with other medicinal products and other forms of interaction

HABIFEN – 600 may interact with aspirin, naproxen, celecoxib, diclofenac, indomethacin, meloxicam, and other heart or blood pressure medicine such as benazepril, enalapril, Lisinopril, quinapril, ramipril, lithium, diuretics (water pills) such as furosemide, methotrexate, steroids (prednisone and others) or a blood thinner such as warfarin

4.6 Pregnancy and lactation

Use in pregnancy and lactation is not recommended. Regular use of Non – steroidal Anti – inflammatory drugs during the third trimester of pregnancy, may result in premature closure of the foetal ductus arteriosis in uterus and possibly in persistent pulmonary hypertension of the newborn.

4.7 Effects on ability to drive and use machines

Not known.

4.8 Undesirable effects

Common adverse include nausea, dyspepsia, gastrointestinal ulceration / bleeding, raised liver enzymes, diarrhea, constipation, epitaxis, headache, dizziness, priapism, rash, salt and fluid retention and hypertension. A study from 210 has shown regular use of NSAIDs was associated with an increase in hearing loss. In frequent adverse effects include esophageal ulceration, heart failure, hyperkalaemia and renal impairment, confusion and bronchospasm. Ibuprofen can exacerbate asthma, sometimes fattaly.

Module 1: Administrative Information & Prescribing Information.

4.9 Overdose

Most symptoms are an excess of the pharmacological action of ibuprofen and include abdominal pain, nausea, vomiting, drowsiness, dizziness, headache, tinnitus and nystagmus.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group:

Ibuprofen:

ATC code: M01AE51

Non Steroidal Anti-inflammatory products

5.2 Pharmacokinetic properties

Ibuprofen is rapidly absorbed from the gastrointestinal tract and peak – plasma concerntrations occur about 1-2 hours after ingestion. It is rapidly metabolized and is excreted in the urine mainly as metabolites and their conjugates.

5.3 Preclinical safety data

Not Applicable.

Module 1: Administrative Information & Prescribing Information.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients:

The excipients used in the formulation of HABIFEN-600 Tablets are mentioned as follows:

- Starch
- * Talc
- Methyl Paraben
- Propyl Paraben
- Dicalcium Phosphate
- Magnesium Stearate
- ❖ Sodium Starch Glycolate
- Colloidal Silicon Dioxide
- Stearic Acid
- Ultracoat AQ Pink

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 Months from Date of Manufacturing.

6.4 Special precautions for storage

Do not store above 30°C. Protect from Light.

6.5 Nature and contents of container <and special equipment for use, administration or implantation>

An Alu Pvc blister of 10 tablets is packed in carton along with pack insert.

Product Name: HABIFEN-600 TABLETS	

Module 1: Administrative Information & Prescribing Information.

6.6 Special precautions for disposal <and other handling>

Any unused medicinal products and waste materials should be disposed of in accordance with local requirements.

Module 1: Administrative Information & Prescribing Information.

7. <APPLICANT/SUPPLIER>

Applicant:

Name : Habmay Pharmacy Ltd.

Address : P.O.Box No. AS81, Asawasi - Kumasi, Ghana.

Telephone Number : 03220-38998.

E-mail : habmay1010@yahoo.com Web : www.habmaypharmacy.com

Supplier:

Name : MERCURY HEALTHCARE PVT LTD
Address : 12-B, Gr. Floor, Girichhaya, Loyalka Estate,

Chowpatty Band Stand, Mumbai, 400 002.

Telephone Number: ++91-22-66172224/5

E-mail : info@mercuryhealthcare,net Web : www.mercuryhealthcare.net

8. FDA APPLICATION NUMBER

FDA/DRID/DER/FHR/17/0495

9. DATE OF <REGISTRATION> / <RENEWAL OF REGISTRATION>

Date of Registration : 04/05/2017.

10. DATE OF REVISION OF THE TEXT

24.07.2020.